Evidence map›Paper›PMID 42440057›Full record

ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2026

Real-world patterns of healthcare use, costs, and survival in diffuse large B-cell lymphoma: a nationwide Swedish register study.

Eva Herweijer, Kaisa Miikkulainen, Oskar Eklund, Brett Doble, Christoffer Holmberg, Viktor Hedlöf Kanje, Robyn Thorén, Christina Victoria Jones, Magnus Björkholm

Abstract read
PubMed Publisher
In one paragraph

Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Eva HerweijerCiencia Research AB, Drottninggatan 33, 111 51, Stockholm, Sweden.
Kaisa MiikkulainenGilead Sciences Sweden AB, Solna, Stockholm, Sweden.
Oskar EklundGilead Sciences Sweden AB, Solna, Stockholm, Sweden.
Brett DobleKite, a Gilead Company, Santa Monica, USA.
Christoffer HolmbergGilead Sciences Sweden AB, Solna, Stockholm, Sweden.
Viktor Hedlöf KanjeGilead Sciences Sweden AB, Solna, Stockholm, Sweden.
Robyn ThorénCiencia Research AB, Drottninggatan 33, 111 51, Stockholm, Sweden. robyn.thoren@cienciaresearch.com.ORCID http://orcid.org/0000-0001-7823-4147
Christina Victoria JonesCiencia Research AB, Drottninggatan 33, 111 51, Stockholm, Sweden.
Magnus BjörkholmDepartment of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo describe healthcare resource utilization (HCRU), direct costs, and survival of DLBCL patients in Sweden.

methodsThis retrospective cohort study followed adult patients with DLBCL from 2015 to 2023 using Swedish national registers. Time in specialty care was calculated as days per-person-year (PPY). Nordic diagnosis-related-group weights were used to estimate costs.

results7,503 patients were diagnosed with DLBCL. Median age was 73.0 years; 56.9% male and 55.0% had ≥ 1 comorbidity. On average, patients spent 17.6 days (4.8% annually) PPY in care, with average costs of €15,417 PPY. HCRU was highest in the first and second year with 41.7 days (11.4%) and 12.6 days (3.5%) in care, respectively. Average time in care declined from 13.7 days (3.8%) in 2015 to 11.9 days (3.3%) in 2019, then stabilized. Overall survival was 76.5% (95%CI: 75.5-77.4) and 68.9% (95%CI: 67.9-70.0) at 1 and 2 years from diagnosis.

conclusionsDLBCL patients spent considerable time in specialist care, especially in the first two years post-diagnosis. Care use and costs remained stable over the period. This study provides the first population-level estimates of HCRU and direct costs for DLBCL in Sweden, offering valuable context for current management and future integration of evolving treatment strategies.

Indexed as

CAR T-cell therapyDiffuse large B-cell lymphomaDirect costsHealthcare resource utilizationReal-world dataSpecialist care

Identifiers

PMID42440057

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.